<DOC>
	<DOCNO>NCT00571584</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial evaluate efficacy safety two dose schedule activate recombinant human factor VII treatment joint bleeds haemophilia patient inhibitor .</brief_summary>
	<brief_title>High Dose Activated Recombinant Human Factor VII Treatment Mild/Moderate Joint Bleeds Haemophilia Patients With Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Diagnosed congenital haemophilia A B inhibitor factor VIII IX , respectively A history 3 joint bleeds last 12 month Joint bleed within 7 day prior trial start Treatment bleed within last 5 day prior trial start Clinically relevant coagulation disorder congenital haemophilia A B</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>